# NFκB p65 (C-20): sc-372



The Power to Question

## **BACKGROUND**

Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor NF $\kappa$ B (p50 and p65) and the *Drosophila* maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp  $\kappa$ B sequence in the immunoglobulin  $\kappa$  light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF $\kappa$ B is activated and NF $\kappa$ B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdl, binds to p50 and regulates its activity.

# **CHROMOSOMAL LOCATION**

Genetic locus: RELA (human) mapping to 11q13.1; Rela (mouse) mapping to 19 A.

## **SOURCE**

 $NF_{\kappa}B$  p65 (C-20) is available as either rabbit (sc-372) or goat (sc-372-G) affinity purified polyclonal antibody raised against a peptide mapping at the C-terminus of  $NF_{\kappa}B$  p65 of human origin.

# **PRODUCT**

Each vial contains either 100  $\mu g$  (sc-372) or 200  $\mu g$  (sc-372-G) lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-372 X, 100  $\mu g/0.1$  ml.

 $NF\kappa B$  p65 (C-20) is available conjugated to agarose (sc-372 AC), 500  $\mu g/$  0.25 ml agarose in 1 ml, for IP.

Blocking peptide available for competition studies, sc-372 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

#### **APPLICATIONS**

NF $\kappa$ B p65 (C-20) is recommended for detection of NF $\kappa$ B p65 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000). NF $\kappa$ B p65 (C-20) is also recommended for detection of NF $\kappa$ B p65 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for NF $\kappa$ B p65 siRNA (h): sc-29410, NF $\kappa$ B p65 siRNA (m): sc-29411, NF $\kappa$ B p65 shRNA Plasmid (h): sc-29410-SH, NF $\kappa$ B p65 shRNA Plasmid (m): sc-29411-SH, NF $\kappa$ B p65 shRNA (h) Lentiviral Particles: sc-29410-V and NF $\kappa$ B p65 shRNA (m) Lentiviral Particles: sc-29410-V


 $NF\kappa B$  p65 (C-20) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.


Molecular Weight of NFκB p65: 65 kDa.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **DATA**





Western blot analysis of NF $\kappa$ B p65 phosphorylation in untreated (**A,D**), TNF $\alpha$  and calyculin A treated (**B,E**) and TNF $\alpha$ , calyculin and lambda protein phosphatase (sc-200312A) treated (**C,F**) HeLa whole cell lysates. Antibodies tested include p-NF $\kappa$ B p65 (Ser 311): sc-33039 (**A,B,C**) and NF $\kappa$ B p65 (C-20): sc-372 (**D,E,F**).

NF<sub>K</sub>B p65 (C-20): sc-372. (**A**) Immunofluorescence staining of methanol-fixed NIH/3T3 cells showing cytoplasmic staining, (**B**) NF<sub>K</sub>B p65 (C-20)-G: sc-372-G. Immunofluorescence staining of methanol-fixed A-431 cells showing cytoplasmic staining.

# **SELECT PRODUCT CITATIONS**

- Jones, H.W., et al. 1989. The place of colposcopy and related systems in gynecological practice and research. J. Reprod. Med. 34: 75.
- Zhang, Z., et al. 2015. Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. Arthritis Rheumatol. 67: 785-796.
- Xie, Z., et al. 2015. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia 29: 2347-2354.
- Simon, P.S., et al. 2015. The NFκB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription. BMC Cancer 15: 770.
- Todorovi , N., et al. 2016. Olanzapine modulation of hepatic oxidative stress and inflammation in socially isolated rats. Eur. J. Pharm. Sci. 81: 94-102.
- 6. Bugajev, V., et al. 2016. Negative regulatory roles of ORMDL3 in the FcɛRl-triggered expression of proinflammatory mediators and chemotactic response in murine mast cells. Cell. Mol. Life Sci. 73: 1265-1285.
- 7. Chaudhary, P., et al. 2016. HSP70 binding protein 1 (HspBP1) suppresses HIV-1 replication by inhibiting NF- $\kappa$ B mediated activation of viral gene expression. Nucleic Acids Res. 44: 1613-1629.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.



Try NFkB p65 (F-6): sc-8008 or NFkB p65 (A-12): sc-514451, our highly recommended monoclonal aternatives to NFkB p65 (C-20). Also, for AC, HRP, FITC, PE, Alexa Fluor<sup>®</sup> 488 and Alexa Fluor<sup>®</sup> 647 conjugates, see NFkB p65 (F-6): sc-8008.